ASCO 2021 Lung Cancer
Early-Stage NSCLC: Promising Data for Neoadjuvant Durvalumab with Stereotactic Body Radiotherapy
A recently published phase 2 study in Lancet Oncology showed that the combination of neoadjuvant durvalumab with stereotactic body radiotherapy (SBRT) is safe and grants a nearly 55% major pathologic response rates among...
Read MoreDurvalumab after chemoradiation proven safe in elderly NSCLC patients
The addition of durvalumab after chemoradiation (CRT) in unresectable stage 3 non-small cell lung cancer (NSCLC) can be safely delivered in elderly patients ≥70 years with comparable improvement in overall survival (OS), as...
Read MoreDoubling overall survival in US veterans with stage 3 non-small cell lung cancer
Median overall survival doubled for veterans with stage 3 non-small cell lung cancer who received chemoradiotherapy plus durvalumab, as compared to those receiving chemoradiotherapy alone, according to a new study presented at...
Read More5-year PACIFIC data hold strong in NSCLC
Updated findings of the PACIFIC trial showed an overall survival (OS) rate of 43% after 5 years of treatment with durvalumab, which has . Physician’s Weekly spoke with Dr. Camille Hertzka, vice president and head of Oncology, US...
Read MoreDoubling overall survival in US veterans with stage 3 non-small cell lung cancer
Median overall survival doubled for veterans with stage 3 non-small cell lung cancer who received chemoradiotherapy plus durvalumab, as compared to those receiving chemoradiotherapy alone, according to a new study presented at...
Read More
Novel Imaging Biomarkers Identify Stage III NSCLC Therapy Response
A study evaluating the utility of novel imaging biomarkers (radiomics) to distinguish patients...
Read MorePatritumab deruxtecan (HER3-DXd) in EGFR TKI-resistant NSCLC
Patritumab deruxtecan (HER3-DXd), an antibody drug conjugate consisting of a monoclonal antibody to HER3 attached to a topoisomerase I, demonstrates anti-tumour activity across various EGFR TKI resistance mechanisms in heavily...
Read MoreSustained efficacy of nivolumab/ipilimumab plus 2 cycles of chemotherapy in NSCLC
A 2-year update of the CheckMate 9LA trial shows sustained benefit of first-line treatment with nivolumab plus ipilimumab plus 2 cycles of chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung...
Read More
Pembro-Chemo Combo Holds Promise for Stage III NSCLC
Good anti-tumor activity and manageable safety profile seen When added to concurrent...
Read More
Amivantamab/Lazertinib Combo Shows Benefit in Relapsed NSCLC
Confirmed response seen in patients who relapse after osimertinib Patients with non-small cell...
Read More
Sotorasib Demonstrates Rapid, Durable Response in KRAS p.G12C-Mutated NSCLC
Objective response observed at 1.4 months Targeted therapies have greatly improved outcomes in...
Read MoreSurvival Trends of NSCLC Diagnosed in 2012 vs 2019
Significant improvements in mortality among non-small cell lung cancer (NSCLC) cancer patients have been reported over the past 2 decades, according to Surveillance, Epidemiology, and End Results Program (SEER) data. The timing...
Read MorectDNA Predicts Early Relapse in NSCLC
Liquid biopsies based on circulating tumor DNA (ctDNA) analysis are being investigated for detection of residual disease and recurrence in patients with early-stage non-small cell lung cancer (NSCLC). Due to low ctDNA levels in...
Read MoreIO-Only or in Chemo-IO Regimens NSCLC Subgroups
Immunotherapy (IO) + chemotherapy ± anti-angiogenics comprise FDA-approved 1L regimens for metastatic non-small cell lung cancer (NSCLC), with IO-only therapy approved only for PD-L1+ NSCLC. Patients with PD-L1 scores from...
Read MoreLong-Term Survival of Adenosquamous Carcinoma vs SCC and Adenocarcinoma
Survival outcomes for patients with adenosquamous carcinoma of the lung are not well understood by virtue of reduced prevalence. To address this, a recent study sought to compare the long-term survival among patients with...
Read MoreAn Insider’s Guide to ASCO 2021: A Focus on Lung Cancer
The ASCO Annual Meeting enters its second year in a virtual setting June 4-8, 2021, to ensure the safety and health of attendees while delivering groundbreaking science in oncology and timely information on clinical application...
Read MoreASCO 2021: How does high intensity interval training impact advanced NSCLC?
Patients with advanced non-small cell lung cancer (NSCLC) experience fatigue and physical deconditioning, altering their quality of life (QoL). However, the safety and feasibility of high intensity exercise in advanced NSCLC has...
Read More